Public Meeting on Patient-Focused Drug Development for Autism
On May 4, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Autism. FDA is interested in obtaining patient perspectives on the impact of autism on daily life and patient views on treatment approaches.
May 4, 2017
1:00 p.m. - 5:00 p.m.
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)
To register for this meeting, visit: Public Meeting on Patient-Focused Drug Development for Autism.
We recommend registering early for the meeting.
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 5, 2017.
FDA is interested in patient responses to the questions listed in the Federal Register Notice.
Access the public docket here: Docket Information
- Webinar: Background on FDA and Patient-Focused Drug Development
- Meeting Agenda
- Autism Patient Focused Drug Development Meeting Slides
- Meeting Recording 1
- Meeting Recording 2
- The Voice of The Patient: Autism